Sun Pharma debuts Winlevi

Winlevi provides a topical treatment for acne vulgaris in patients aged 12 years old and older.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Sun Pharma is offering Winlevi (clascoterone) cream, 1%.

Winlevi, a first-in-class topical androgen receptor inhibitor, was approved by the Food and Drug Administration in August 2020 for the topical treatment of acne vulgaris in patients aged 12 years of old and older. 

[Read more: Sun Pharma intros 2 generics]

Winlevi is the first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40  years. 

Sun Pharma noted that Winlevi works by inhibiting the effects of androgen receptors in cells of the sebaceous glands (oil producing glands in the skin) to help reduce sebum (oil) production and inflammation, and that it is suitable for use in both males and females.

[Read more: Sun Pharma, Cassiopea ink license, supply agreements for Winlevi]